Femasys Inc. Common Stock (FEMY)
Stock · NASDAQ · Health Care
$1.65as of 10/16/2026
Price chart
FEMY Signal Track Record
How signals performed across all stocks →What FEMY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 29 | -3.0% | 45% | September 29, 2026 |
| Volume Spike | 25 | -8.0% | 32% | September 29, 2026 |
| Bollinger Band Breakout | 17 | -9.4% | 35% | May 6, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -2.1% | 22% | April 21, 2025 |
| Any 20-session window (baseline) | -7.8% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FEMY
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an end…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 51
- Website
- www.femasys.com/
Fundamentals
- 1-day range
- $1.47$1.74
- Market cap
- $8.91M
- P/E (trailing)
- —
- P/E (forward)
- -0.71
- EPS (trailing)
- $-4.41
- Dividend yield
- —
- Beta
- -2.34
- Avg. volume
- 724.3K
How Femasys Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 27, 2025 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Femasys Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FEMYFemasys Inc. Common Stock$1.65▼ 4.90%Market cap $8.91MP/E —$1.67$22.2
- CODXCo-Diagnostics Inc. Common Stock$0.654▼ 8.53%Market cap $9.91MP/E —$0.746$46.5
- SINTSiNtx Technologies Inc. Common Stock$1.74▼ 1.69%Market cap $10.36MP/E —$1.4$4.5
- PMIPicard Medical Inc. Common Stock$12.75▲ 27.50%Market cap $7.27MP/E —$2.65$684
- ICCMIceCure Medical Ltd. Ordinary Shares$1.06▲ 1.92%Market cap $10.55MP/E —$1.04$29.46
- NVNOenVVeno Medical Corporation Common Stock$7.47▼ 5.74%Market cap $6.93MP/E —$7.01$30.8
- MODDModular Medical Inc. Common Stock$2.32▲ 7.18%Market cap $10.99MP/E —$1.72$18.76
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FEMY Femasys Inc. Common Stock | $8.91M | — | $1.65 | ▼ 4.90% | $1.67$22.2 |
| CODX Co-Diagnostics Inc. Common Stock | $9.91M | — | $0.654 | ▼ 8.53% | $0.746$46.5 |
| SINT SiNtx Technologies Inc. Common Stock | $10.36M | — | $1.74 | ▼ 1.69% | $1.4$4.5 |
| PMI Picard Medical Inc. Common Stock | $7.27M | — | $12.75 | ▲ 27.50% | $2.65$684 |
| ICCM IceCure Medical Ltd. Ordinary Shares | $10.55M | — | $1.06 | ▲ 1.92% | $1.04$29.46 |
| NVNO enVVeno Medical Corporation Common Stock | $6.93M | — | $7.47 | ▼ 5.74% | $7.01$30.8 |
| MODD Modular Medical Inc. Common Stock | $10.99M | — | $2.32 | ▲ 7.18% | $1.72$18.76 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy ExpandsYahoo · 10/8/2026
- Femasys to Exhibit at the ASRM 2026 Scientific Congress & ExpoYahoo · 10/8/2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 9/16/2026
- Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s CareYahoo · 9/15/2026
Insider Activity
Insider Actions →- Mifek Jeffrey Gerald · August 7, 2026 · Grant3.1K
- Mifek Jeffrey Gerald · August 7, 2026 · Buy3.1K @ $3.2
- Sipos Jeremy Alexander · August 7, 2026 · Grant3.1K
- Sipos Jeremy Alexander · August 7, 2026 · Buy3.1K @ $3.2
- Canning John Charles · August 7, 2026 · Grant4.4K
- Lee-Sepsick Kathy · August 7, 2026 · Grant15.6K
- Canning John Charles · August 7, 2026 · Buy4.4K @ $3.2
- Lee-Sepsick Kathy · August 7, 2026 · Buy15.6K @ $3.2
- Elefant Dov · August 7, 2026 · Grant15.6K
- Elefant Dov · August 7, 2026 · Buy15.6K @ $3.2
- Mifek Jeffrey Gerald · July 6, 2026 · Grant6.3K
- Eichenbaum Kenneth D. · June 24, 2026 · Grant880
- Uzialko Edward R · June 24, 2026 · Grant880
- Alistair Milnes · June 24, 2026 · Grant880
- Larsen Charles · June 24, 2026 · Grant880
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Femasys to Showcase FemaSeed at ASRM 2026
Femasys announced it will exhibit its FemaSeed fertility treatment at the ASRM 2026 Scientific Congress & Expo. This move signals an expansion of the company's commercialization strategy as it seeks to increase visibility for its product. The stock currently trades near its 52-week low, with an RSI of 36.7 indicating recent weakness.
Femasys to Showcase FemaSeed at ASRM 2026. Femasys announced it will exhibit its FemaSeed fertility treatment at the ASRM 2026 Scientific Congress & Expo. This move signals an expansion of the company's commercialization strategy as it seeks to increase visibility for its product. The stock currently trades near its 52-week low, with an RSI of 36.7 indicating recent weakness.